X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemistry (144) 144
metallurgy (144) 144
microbiology (137) 137
beer (136) 136
biochemistry (136) 136
compositions or test papers therefor (136) 136
condition-responsive control in microbiological orenzymological processes (136) 136
enzymology (136) 136
measuring or testing processes involving enzymes, nucleicacids or microorganisms (136) 136
mutation or genetic engineering (136) 136
processes of preparing such compositions (136) 136
spirits (136) 136
vinegar (136) 136
wine (136) 136
investigating or analysing materials by determining theirchemical or physical properties (39) 39
measuring (39) 39
physics (39) 39
testing (39) 39
human necessities (38) 38
hygiene (38) 38
medical or veterinary science (38) 38
preparations for medical, dental, or toilet purposes (36) 36
index medicus (19) 19
humans (18) 18
organic chemistry (18) 18
oncology (15) 15
carcinoma, non-small-cell lung - drug therapy (14) 14
lung neoplasms - drug therapy (14) 14
female (13) 13
male (13) 13
chemotherapy (12) 12
erlotinib (12) 12
carcinoma, non-small-cell lung - genetics (11) 11
lung neoplasms - genetics (11) 11
compositions thereof (10) 10
culture media (10) 10
gefitinib (10) 10
microorganisms or enzymes (10) 10
middle aged (10) 10
propagating, preserving or maintaining microorganisms (10) 10
specific therapeutic activity of chemical compounds ormedicinal preparations (10) 10
aged (9) 9
combinatorial chemistry (9) 9
heterocyclic compounds (9) 9
libraries, e.g. chemical libraries, in silicolibraries (9) 9
mutation (9) 9
protein kinase inhibitors - therapeutic use (9) 9
adult (8) 8
biomarkers (8) 8
erlotinib hydrochloride (8) 8
peptides (8) 8
receptor, epidermal growth factor - genetics (8) 8
cancer (7) 7
carcinoma, non-small-cell lung - mortality (7) 7
epidermal growth factor (7) 7
lung cancer, non-small cell (7) 7
lung neoplasms - mortality (7) 7
open-label (7) 7
quinazolines - therapeutic use (7) 7
receptor, epidermal growth factor - antagonists & inhibitors (7) 7
tumors (7) 7
egfr (6) 6
gene expression (6) 6
lung neoplasms - pathology (6) 6
multicenter (6) 6
respiratory system (6) 6
treatment outcome (6) 6
1st-line treatment (5) 5
antineoplastic agents - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
biochemistry & molecular biology (5) 5
carcinoma, non-small-cell lung - metabolism (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
cell biology (5) 5
cyanobacteria (5) 5
epidermal growth factor receptors (5) 5
growth-factor-receptor (5) 5
hematology, oncology and palliative medicine (5) 5
lung cancer (5) 5
lung neoplasms - metabolism (5) 5
non-small cell lung carcinoma (5) 5
plant sciences (5) 5
proteins (5) 5
steady-state photosynthesis (5) 5
survival (5) 5
aged, 80 and over (4) 4
bicarbonate transport (4) 4
cancer therapies (4) 4
carbon dioxide (4) 4
care and treatment (4) 4
concentrating mechanism (4) 4
disease-free survival (4) 4
medicine, research & experimental (4) 4
non-small-cell lung cancer (4) 4
patients (4) 4
photosynthesis (4) 4
receptor, epidermal growth factor - metabolism (4) 4
research (4) 4
adenocarcinoma (3) 3
cell lung-cancer (3) 3
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (172) 172
French (51) 51
German (20) 20
Spanish (19) 19
Chinese (15) 15
Korean (11) 11
Portuguese (10) 10
Danish (3) 3
Slovenian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 6, pp. 521 - 529
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 300 - 308
Summary Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head... 
Hematology, Oncology and Palliative Medicine | GEFITINIB | THERAPY | ONCOLOGY | KRAS | DOCETAXEL | III TRIAL | EGFR | Erlotinib Hydrochloride | Immunohistochemistry | Lung Neoplasms - drug therapy | Prospective Studies | Guanine - analogs & derivatives | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Early Termination of Clinical Trials | Receptor, Epidermal Growth Factor - metabolism | Carcinoma, Non-Small-Cell Lung - secondary | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Lung Neoplasms - enzymology | Europe | Kaplan-Meier Estimate | Treatment Outcome | Chi-Square Distribution | Pemetrexed | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Guanine - administration & dosage | Medical colleges | Care and treatment | Prognosis | Lung cancer | Oncology, Experimental | Clinical trials | Research | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Cancer patients | Chemotherapy | Erlotinib | Universities and colleges | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2014, Volume 9, Issue 2, p. e89518
Journal Article
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 01/2010, Volume 14, Issue 1‐2, pp. 51 - 69
•  Introduction •  Literature review ‐  Molecular biology of EGFR mutations ‐  Clinical characteristics of NSCLC patients with EGFR mutations ‐  Genetic... 
lung cancer | mutation | epidermal growth factor receptor | erlotinib | adenocarcinoma | gefitinib | tyrosine kinase inhibitor | chemotherapy | Adenocarcinoma | Chemotherapy | Erlotinib | Tyrosine kinase inhibitor | Lung cancer | Mutation | Gefitinib | Epidermal growth factor receptor | MEDICINE, RESEARCH & EXPERIMENTAL | GROWTH-FACTOR-RECEPTOR | IN-SITU-HYBRIDIZATION | TREATED JAPANESE PATIENTS | GEFITINIB SENSITIVITY | CELL BIOLOGY | CHEMOTHERAPY-NAIVE PATIENTS | CLINICOPATHOLOGICAL CHARACTERISTICS | PHASE-II TRIAL | BRONCHIOLOALVEOLAR-CARCINOMA | GENE COPY NUMBER | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Review Literature as Topic | Sensitivity and Specificity | Publication Bias | Retrospective Studies | Carcinoma, Non-Small-Cell Lung - drug therapy | Kinases | Clinical outcomes | Cells | Tyrosine | Permutations | Sensitivity analysis | Statistical analysis | Epidermal growth factor receptors | Clinical trials | Non-small cell lung carcinoma | Cancer therapies | Patients | Subgroups | Literature reviews | Studies | Epidermal growth factor | Data search | Ligands | Median (statistics) | Molecular biology | Growth factors | Tumors | Reviews
Journal Article
Molecular Biology and Evolution, ISSN 0737-4038, 10/2013, Volume 30, Issue 10, pp. 2328 - 2346
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2015, Volume 21, Issue 14, pp. 3196 - 3203
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 08/2014, Volume 18, Issue 8, pp. 1519 - 1539
Patients with non‐small‐cell lung cancer ( NSCLC ) appear to gain particular benefit from treatment with epidermal growth factor receptor ( EGFR )... 
mutation | afatinib | NSCLC | epidermal growth factor receptor | erlotinib | tyrosine‐kinase inhibitor | non‐small‐cell lung cancer | gefitinib | first line | EGFR | icotinib | Tyrosine-kinase inhibitor | Icotinib | Afatinib | Erlotinib | First line | Non-small-cell lung cancer (NSCLC) | Epidermal growth factor receptor (EGFR) | Mutation | Gefitinib | GENE-MUTATIONS | MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | GROWTH-FACTOR-RECEPTOR | epidermal growth factor receptor (EGFR) | PROGRESSION-FREE SURVIVAL | FRONT-LINE CHEMOTHERAPY | non-small-cell lung cancer (NSCLC) | tyrosine-kinase inhibitor | CELL BIOLOGY | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | CHEMOTHERAPY-NAIVE PATIENTS | PHASE-II TRIAL | MOLECULAR PREDICTORS | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Meta-Analysis as Topic | Prognosis | Carcinoma, Non-Small-Cell Lung - genetics | Lung Neoplasms - mortality | Humans | Survival Rate | Mutation - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Review Literature as Topic | Carcinoma, Non-Small-Cell Lung - drug therapy | Care and treatment | Chemotherapy | Genetic aspects | Lung cancer, Non-small cell | Patient outcomes | Cancer | Epidermal growth factor | Kinases | Cancer therapies | Lung cancer | Tyrosine | Permutations | Epidermal growth factor receptors | Medical services | Non-small cell lung carcinoma | Oncology | Disease control | Patients | Datasets | Studies | Biopsy | Writing | Growth factors | Tumors | Original
Journal Article
Nature Medicine, ISSN 1078-8956, 10/2018, Volume 24, Issue 10, pp. 1611 - 1624
Journal Article